INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim today announced data from the landmark 52-week DYNAGITO® trial which show that in people with COPD (chronic obstructive pulmonary di…
Final results from landmark DYNAGITO® trial published in The Lancet Respiratory Medicine1
INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim today announced data from the landmark 52-week DYNAGITO® trial which show that in people with COPD (chronic obstructive pulmonary di…